{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T01:22:56Z","timestamp":1793755376830,"version":"4.6.1"},"reference-count":98,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,4,14]],"date-time":"2023-04-14T00:00:00Z","timestamp":1681430400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>The use of chimeric antigen receptor (CAR) T lymphocytes in the treatment of refractory or relapsed (R\/R) B cell acute lymphoblastic leukemia (B-ALL) has meant a radical change in the prognosis of these patients, whose chances of survival with conventional treatment are very low. The current probability of event-free survival by R\/R B-ALL patients treated using anti-CD 19 CART cell therapy is as high as 50-60% at 1.5 years, which is a very important advance for this group of very ill patients. Although most patients (70 to 94%) achieve complete remission (CR), the main problem continues to be relapse of the disease. Most relapses, both in clinical trials and real-world evidence, are due to failure of CAR-T cell expansion or limited CAR-T persistence. However, despite the adequate functioning of infused CART lymphocytes, the tumor cells of an important group of patients manage to evade CAR-T attack, resulting in a CD 19-negative relapse. Several mechanisms have been described that may be able to produce the escape of leukemic cells, such as acquired mutations and alternative splicing of the CD19 antigen, CD19 epitope loss or masking, leukemia lineage switching, and trogocytosis. In the present review, we comprehensively analyze the leukemic cell escape mechanisms, the incidence of CD19-negative relapse reported in clinical trials and real-world evidence (outside clinical trials), and provide an update on the main lines of current research into the prevention of leukemia evasion.<\/jats:p>","DOI":"10.3389\/fimmu.2023.1165870","type":"journal-article","created":{"date-parts":[[2023,4,14]],"date-time":"2023-04-14T05:18:55Z","timestamp":1681449535000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":58,"title":["Failure of ALL recognition by CAR T cells: a review of CD 19-negative relapses after anti-CD 19 CAR-T treatment in B-ALL"],"prefix":"10.3389","volume":"14","author":[{"given":"Clara","family":"Aparicio-P\u00e9rez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MDolores","family":"Carmona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karim","family":"Benabdellah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Concha","family":"Herrera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,4,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"83","DOI":"10.3322\/caac.21219","article-title":"Childhood and adolescent cancer statistics, 2014","volume":"64","author":"Ward","year":"2014","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21654","article-title":"Cancer statistics, 2021","volume":"71","author":"Siegel","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2020.11583","article-title":"Pathogenesis of pediatric b-cell acute lymphoblastic leukemia: Molecular pathways and disease treatments","volume":"20","author":"Huang","year":"2020","journal-title":"Oncol Lett"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1215134","article-title":"Chimeric antigen receptor-modified T cells for acute lymphoid leukemia","volume":"368","author":"Grupp","year":"2013","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with b-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0146-z","article-title":"Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia","volume":"24","author":"Orlando","year":"2018","journal-title":"Nat Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-02-769208","article-title":"Intent-To-Treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults","volume":"129","author":"Gardner","year":"2017","journal-title":"Blood"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(14)61403-3","article-title":"T Cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: A phase 1 dose-escalation trial","volume":"385","author":"Lee","year":"2015","journal-title":"Lancet (London England)"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"New Engl J Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709919","article-title":"Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia","volume":"378","author":"Park","year":"2018","journal-title":"N Engl J Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13236067","article-title":"T Cell engaging immunotherapies, highlighting chimeric antigen receptor (CAR) T cell therapy","volume":"13","author":"De Bousser","year":"2021","journal-title":"Cancers"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020003092","article-title":"Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma","volume":"4","author":"Pasquini","year":"2020","journal-title":"Blood Adv"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-021-01281-7","article-title":"Determinants of CD19-positive vs CD19-negative relapse after tisagenlecleucel for b-cell acute lymphoblastic leukemia","volume":"35","author":"Dourthe","year":"2021","journal-title":"Leukemia"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.03585","article-title":"Disease burden affects outcomes in pediatric and young adult b-cell lymphoblastic leukemia after commercial tisagenlecleucel: A pediatric real-world chimeric antigen receptor consortium report","volume":"40","author":"Schultz","year":"2022","journal-title":"J ClinOncol."},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01076","article-title":"Outcomes after nonresponse and relapse post-tisagenlecleucel in children, adolescents, and young adults with b-cell acute lymphoblastic leukemia","volume":"41","author":"Schultz","year":"2023","journal-title":"J ClinOncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021006393","article-title":"Real-world use of tisagenlecleucel in infant acute lymphoblastic leukemia","volume":"6","author":"Moskop","year":"2022","journal-title":"Blood Adv"},{"key":"B17","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1200\/JCO.21.01405","article-title":"Blinatumomab nonresponse and high-disease burden are associated with inferior outcomes after CD19-CAR for b-ALL","volume":"40","author":"Myers","year":"2021","journal-title":"J ClinOncol."},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022007423","article-title":"Preinfusion factors impacting relapse immunophenotype following CD19 CAR T cells","volume":"7","author":"Lamble","year":"2022","journal-title":"Blood Adv"},{"key":"B19","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1182\/blood.2020009098","article-title":"KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed\/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results","volume":"138","author":"Shah","year":"2021","journal-title":"Blood"},{"key":"B20","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/S0140-6736(21)01222-8","article-title":"KTE-X19 for relapsed or refractory adult b-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study","volume":"398","author":"Shah","year":"2021","journal-title":"Lancet"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021014892","article-title":"Approval of brexucabtageneautoleucel for adults with relapsed and refractory acute lymphocytic leukemia","volume":"140","author":"Frey","year":"2022","journal-title":"Blood"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyac163","article-title":"FDA Approval summary: BrexucabtageneAutoleucel for treatment of adults with relapsed or refractory b-cell precursor acute lymphoblastic leukemia","volume":"27","author":"Bouchkouj","year":"2022","journal-title":"Oncologist"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-019-0184-6","article-title":"Mechanisms of resistance to CAR T cell therapy","volume":"16","author":"Shah","year":"2019","journal-title":"Nat Rev ClinOncol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"73","DOI":"10.4049\/jimmunol.170.1.73","article-title":"CD19 function in early and late b cell development: I. maintenance of follicular and marginal zone b cells requires CD19-dependent survival signals","volume":"170","author":"Otero","year":"2003","journal-title":". J Immunol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/s1074-7613(02)00426-0","article-title":"The physiologic role of CD19 cytoplasmic tyrosines","volume":"17","author":"Wang","year":"2002","journal-title":"Immunity"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1186\/2162-3619-1-36","article-title":"CD19: a biomarker for b cell development, lymphoma diagnosis and therapy","volume":"1","author":"Wang","year":"2012","journal-title":"ExpHematolOncol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1038\/s41467-021-21168-6","article-title":"Single-cell profiling identifies pre-existing CD19-negative subclones in a b-ALL patient with CD19-negative relapse after CAR-T therapy","volume":"12","author":"Rabilloud","year":"2021","journal-title":"Nat Commun"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0000000000000169","article-title":"CD19 isoforms enabling resistance to CART-19 immunotherapy are expressed in b-ALL patients at initial diagnosis","volume":"40","author":"Fischer","year":"2017","journal-title":"J Immunother"},{"key":"B29","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1182\/blood.2021014840","article-title":"CD34+CD19-CD22+ b-cell progenitors may underlie phenotypic escape in patients treated with CD19-directed therapies","volume":"140","author":"Bueno","year":"2022","journal-title":"Blood"},{"key":"B30","article-title":"Structure and domain organization of the CD19 antigen of human, mouse, and guinea pig b lymphocytes","volume":"147","author":"Zhou","year":"1991","journal-title":"Conserv extensive cytoplasmic domain. J Immunol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1038\/nature08909","article-title":"Expansion of the eukaryotic proteome by alternative splicing","volume":"463","author":"Nilsen","year":"2010","journal-title":"Nature"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1038\/nature07509","article-title":"Alternative isoform regulation in human tissue transcriptomes","volume":"456","author":"Wang","year":"2008","journal-title":"Nature"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1038\/nri.2017.19","article-title":"Mechanisms of central tolerance for b cells","volume":"17","author":"Nemazee","year":"2017","journal-title":"Nat Rev Immunol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-15-1020","article-title":"Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART-19 immunotherapy","volume":"5","author":"Sotillo","year":"2015","journal-title":"Cancer Discovery"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0201-9","article-title":"Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic b cell","volume":"24","author":"Ruella","year":"2018","journal-title":"Nat Med"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2021.1992622","article-title":"CD19 epitope masking by tafasitamab leads to delays in subsequent use of CD19 CAR T-cell therapy in two patients with aggressive mature b-cell lymphomas","volume":"63","author":"Fitzgerald","year":"2022","journal-title":"Leuk Lymphoma."},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms12320","article-title":"CD19 CAR immune pressure induces b-precursor acute lymphoblastic leukaemia lineage switch exposing inherent leukaemic plasticity","volume":"7","author":"Jacoby","year":"2016","journal-title":"Nat Commun"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1080\/10428190500086055","article-title":"Congenital MLL-positive b-cell acute lymphoblastic leukemia (B-ALL) switched lineage at relapse to acute myelocytic leukemia (AML) with persistent t(4;11) and t(1;6) translocations and JH gene rearrangement","volume":"46","author":"Jiang","year":"2005","journal-title":"Leuk Lymphoma"},{"key":"B39","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1111\/ijlh.13923","article-title":"To b- or not to b-: A review of lineage switched acute leukemia","author":"Kurzer","year":"2022","journal-title":"Int J Lab Hematol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1111\/j.0960-135X.2004.01366","article-title":"The biological and clinical significance of MLL abnormalities in haematological malignancies","author":"Mitterbauer-Hohendanner","year":"2004","journal-title":"Eur J Clin Invest."},{"key":"B41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.exphem.2021.07.002","article-title":"Does lineage plasticity enable escape from CAR-T cell therapy? lessons from MLL-r leukemia","volume":"100","author":"Liao","year":"2021","journal-title":"ExpHematol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-08-665547","article-title":"Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged b-ALL from CD19 CAR-t-cell therapy","volume":"127","author":"Gardner","year":"2016","journal-title":"Blood"},{"key":"B43","doi-asserted-by":"publisher","first-page":"3869","DOI":"10.1182\/blood-2019-131447","article-title":"Clinical experience of CAR T cell immunotherapy for relapsed and refractory infant ALL demonstrates feasibility and favorable responses","volume":"134","author":"Annesley","year":"2019","journal-title":"Blood"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.3390\/ijms232214255","article-title":"Learning from TCR signaling and immunological synapse assembly to build new chimeric antigen receptors (CARs)","volume":"23","author":"Cassioli","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-18-0442","article-title":"Tumor antigen escape from CAR T-cell therapy","volume":"8","author":"Majzner","year":"2018","journal-title":"Cancer Discov"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-19-0945","article-title":"Tuning the antigen density requirement for CAR T-cell activity","volume":"10","author":"Majzner","year":"2020","journal-title":"Cancer Discovery"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-022-03231-3","article-title":"Host b cells escape CAR-T immunotherapy by reversible downregulation of CD19","volume":"72","author":"Fioretti","year":"2023","journal-title":"Cancer ImmunolImmunother"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002352","article-title":"Hypermethylation of CD19 promoter enables antigen-negative escape to CART-19 in vivo and in vitro","volume":"9","author":"Ledererova","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4441","article-title":"CD22-targeted CAR T cells induce remission in b-ALL that is naive or resistant to CD19-targeted CAR immunotherapy","volume":"24","author":"Fry","year":"2018","journal-title":"Nat Med"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019000692","article-title":"CAR T-cell therapy is effective for CD19-dim b-lymphoblastic leukemia but is impacted by prior blinatumomab therapy","volume":"3","author":"Pillai","year":"2019","journal-title":"Blood Adv"},{"key":"B51","first-page":"1","article-title":"Plasma membrane nibbling: all lymphocytes do it, but why","volume":"9","author":"Hudrisier","year":"2002","journal-title":"ELSO Gaz"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1038\/ni0903-815","article-title":"What is trogocytosis and what is its purpose","volume":"4","author":"Joly","year":"2003","journal-title":"Nat Immunol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1054-1","article-title":"CAR T cell trogocytosis and cooperative killing regulate tumour antigen escape","volume":"568","author":"Hamieh","year":"2019","journal-title":"Nature"},{"key":"B54","doi-asserted-by":"publisher","first-page":"e29123","DOI":"10.1002\/pbc.29123","article-title":"Tisagenlecleucel for treatment of children and young adults with relapsed\/refractory b-cell acute lymphoblastic leukemia","volume":"68","author":"Si Lim","year":"2021","journal-title":"Pediatr Blood Cancer."},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021005564","article-title":"Tisagenlecleucel outcomes in relapsed\/refractory extramedullary ALL: a pediatric real world CAR consortium report","volume":"6","author":"Fabrizio","year":"2022","journal-title":"Blood Adv"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1172\/JCI125423","article-title":"CD19 CAR T cell product and disease attributes predict leukemia remission durability","volume":"129","author":"Finney","year":"2019","journal-title":"J Clin Invest."},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2020.09.027","article-title":"CART19-BE-01: A multicenter trial of ARI-0001 cell therapy in patients with CD19+ Relapsed\/Refractory malignancies","volume":"29","author":"Ort\u00edz-Maldonado","year":"2021","journal-title":"MolTher"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.02262","article-title":"Long-term follow-up of CD19-CAR T-cell therapy in children and young adults with b-ALL","volume":"39","author":"Shah","year":"2021","journal-title":"J ClinOncol."},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25274","article-title":"Locally produced CD19 CAR T cells leading to clinical remissions in medullary and extramedullary relapsed acute lymphoblastic leukemia","volume":"93","author":"Jacoby","year":"2018","journal-title":"Am J Hematol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020001466","article-title":"Efficacy and safety of anti-CD19 CAR T-cell therapy in 110 patients with b-cell acute lymphoblastic leukemia with high-risk features","volume":"4","author":"Zhang","year":"2020","journal-title":"Blood Adv"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1016\/j.omto.2020.06.016","article-title":"Efficacy and safety of CD28- or 4-1BB-Based CD19 CAR-T cells in b cell acute lymphoblastic leukemia","volume":"18","author":"Zhao","year":"2020","journal-title":"MolTherOncolytics"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2020.12.010","article-title":"Systematic review and meta-analysis of CD19-specific CAR-T cell therapy in Relapsed\/Refractory acute lymphoblastic leukemia in the pediatric and young adult population: Safety and efficacy outcomes","volume":"21","author":"Aamir","year":"2021","journal-title":"ClinLymphomaMyelomaLeuk"},{"key":"B63","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1007\/s00262-021-03009-z","article-title":"Factors associated with treatment response to CD19 CAR-T therapy among a large cohort of b cell acute lymphoblastic leukemia","volume":"71","author":"Zhang","year":"2022","journal-title":"Cancer ImmunolImmunother"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2020.06.011","article-title":"Debate: Transplant is still necessary in the era of targeted cellular therapy for acute lymphoblastic leukemia","volume":"20","author":"Khazal","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk."},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2021.784024","article-title":"Chimeric antigen receptor T-cell therapy in paediatric b-cell precursor acute lymphoblastic leukaemia: Curative treatment option or bridge to transplant","volume":"9","author":"Buechner","year":"2022","journal-title":"Front Pediat"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1016\/j.beha.2022.101414","article-title":"Should all CAR-T therapy for acute lymphoblastic leukemia be consolidated with allogeneic stem cell transplant","volume":"35","author":"Marinos","year":"2022","journal-title":"Best Pract Res ClinHaematol"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2021.10.011","article-title":"Factors impacting overall and event-free survival following post-chimeric antigen receptor T cell consolidative hematopoietic stem cell transplantation","volume":"28","author":"Molina","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.00146","article-title":"Multi targeted CAR-T cell therapies for b-cell malignancies","volume":"9","author":"Shah","year":"2019","journal-title":"Front Oncol"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12092523","article-title":"Bispecific chimeric antigen receptor T cell therapy for b cell malignancies and multiple myeloma","volume":"12","author":"Cronk","year":"2020","journal-title":"Cancers (Basel)."},{"key":"B70","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0065-2776(05)88001-0","article-title":"CD22: a multifunctional receptor that regulates b lymphocyte survival and signal transduction","volume":"88","author":"Tedder","year":"2005","journal-title":"AdvImmunol"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.25410","article-title":"Characterization of CD22 expression in acute lymphoblastic leukemia","volume":"62","author":"Shah","year":"2015","journal-title":"Pediatr Blood Cancer."},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-065X.2009.00801.x","article-title":"CD22 and siglec-G: B-cell inhibitory receptors with distinct functions","volume":"230","author":"Nitschke","year":"2009","journal-title":"Immunol Rev"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02235","article-title":"CD22: a regulator of innate and adaptive b cell responses and autoimmunity","volume":"9","author":"Clark","year":"2018","journal-title":"Front Immunol"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2011.559668","article-title":"Flow cytometric study of potential target antigens (CD19, CD20, CD22, CD33) for antibody-based immunotherapy in acute lymphoblastic leukemia: analysis of 552 cases","volume":"52","author":"Raponi","year":"2011","journal-title":"Leuk Lymphoma."},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-020-00856-8","article-title":"Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory b cell acute lymphoblastic leukemia","volume":"13","author":"Dai","year":"2020","journal-title":"J HematolOncol."},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26160","article-title":"Combination of CD19 and CD22 CAR-T cell therapy in relapsed b-cell acute lymphoblastic leukemia after allogeneic transplantation","volume":"96","author":"Liu","year":"2021","journal-title":"Am J Hematol"},{"key":"B77","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s40164-022-00270-5","article-title":"A novel and efficient CD22 CAR-T therapy induced a robust antitumor effect in relapsed\/refractory leukemia patients when combined with CD19 CAR-T treatment as a sequential therapy","volume":"11","author":"Zhang","year":"2022","journal-title":"ExpHematolOncol"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019003293","article-title":"Sequential CD19-22 CAR T therapy induces sustained remission in children with r\/r b-ALL","volume":"135","author":"Pan","year":"2020","journal-title":"Blood"},{"key":"B79","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1182\/blood.2019000017","article-title":"Efficacy and safety of CAR19\/22 T-cell cocktail therapy in patients with refractory\/relapsed b-cell malignancies","volume":"135","author":"Wang","year":"2020","journal-title":"Blood"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcyt.2022.01.011","article-title":"CAR19\/22 T cell cocktail therapy for b-ALL relapsed after allogeneic hematopoietic stem cell transplantation","volume":"24","author":"Yan","year":"2022","journal-title":"Cytotherapy"},{"key":"B81","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1200\/JCO.22.01214","article-title":"Coadministration of CD19- and CD22-directed chimeric antigen receptor T-cell therapy in childhood b-cell acute lymphoblastic leukemia: A single-arm, multicenter, phase II trial","volume":"41","author":"Wang","year":"2022","journal-title":"J ClinOncol"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01497-1","article-title":"CAR t\u2009cells with dual targeting of CD19 and CD22 in pediatric and young adult patients with relapsed or refractory b\u2009cell acute lymphoblastic leukemia: a phase 1 trial","volume":"27","author":"Cordoba","year":"2021","journal-title":"Nat Med"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01436-0","article-title":"CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory b cell malignancies: a phase 1 trial","volume":"27","author":"Spiegel","year":"2021","journal-title":"Nat Med"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022015795","article-title":"CD19\/22 CAR T cells in children and young adults with b-ALL: phase 1 results and development of a novel bicistronic CAR","volume":"140","author":"Shalabi","year":"2022","journal-title":"Blood"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2021.08.033","article-title":"A novel and efficient tandem CD19- and CD22-directed CAR for b cell ALL","volume":"30","author":"Zanetti","year":"2022","journal-title":"MolTher"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1172\/JCI87366","article-title":"Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies","volume":"126","author":"Ruella","year":"2016","journal-title":"J Clin Invest."},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-021-01477-x","article-title":"CD19\/BAFF-r dual-targeted CAR T cells for the treatment of mixed antigen-negative variants of acute lymphoblastic leukemia","volume":"36","author":"Wang","year":"2022","journal-title":"Leukemia"},{"key":"B88","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/s41375-020-0792-2","article-title":"CAR T-cells that target acute b-lineage leukemia irrespective of CD19 expression","volume":"35","author":"Fousek","year":"2021","journal-title":"Leukemia"},{"key":"B89","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.ccell.2019.02.006","article-title":"CD40 ligand-modified chimeric antigen receptor T cells enhance antitumor function by eliciting an endogenous antitumor response","volume":"35","author":"Kuhn","year":"2019","journal-title":"Cancer Cell"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-12-400044","article-title":"Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning","volume":"119","author":"Pegram","year":"2012","journal-title":"Blood"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-11-0103","article-title":"IL-12 release by engineered T cells expressing chimeric antigen receptors can effectively muster an antigen-independent macrophage response on tumor cells that have shut down tumor antigen expression","volume":"71","author":"Chmielewski","year":"2011","journal-title":"Cancer Res"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2018.04.051","article-title":"Engineered tumor-targeted T cells mediate enhanced anti-tumor efficacy both directly and through activation of the endogenous immune system","volume":"23","author":"Avanzi","year":"2018","journal-title":"Cell Rep"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001514","article-title":"Strategy to prevent epitope masking in CAR.CD19+ b-cell leukemia blasts","volume":"9","author":"Quintarelli","year":"2021","journal-title":"J Immunother Cancer."},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019001859","article-title":"A cellular antidote to specifically deplete anti-CD19 chimeric antigen receptor-positive cells","volume":"135","author":"Ruella","year":"2020","journal-title":"Blood"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01585-2","article-title":"Low-affinity CAR T cells exhibit reduced trogocytosis, preventing rapid antigen loss, and increasing CAR T cell expansion","volume":"36","author":"Olson","year":"2022","journal-title":"Leukemia"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0549-5","article-title":"Enhanced CAR T cell expansion and prolonged persistence in pediatric patients with ALL treated with a low-affinity CD19 CAR","volume":"25","author":"Ghorashian","year":"2019","journal-title":"Nat Med"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.00917","article-title":"Durable responses and low toxicity after fast off-rate CD19 chimeric antigen receptor-T therapy in adults with relapsed or refractory b-cell acute lymphoblastic leukemia","volume":"39","author":"Roddie","year":"2021","journal-title":"J ClinOncol."},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01621-1","article-title":"HLA-independent T cell receptors for targeting tumors with low antigen density","volume":"28","author":"Mansilla-Soto","year":"2022","journal-title":"Nat Med"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1165870\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,14]],"date-time":"2023-04-14T05:19:00Z","timestamp":1681449540000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1165870\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,14]]},"references-count":98,"alternative-id":["10.3389\/fimmu.2023.1165870"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2023.1165870","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,14]]},"article-number":"1165870"}}